|
Name |
Aspochalasin P
|
Molecular Formula | C24H35NO4 | |
IUPAC Name* |
(1S,6R,9E,11S,14S,15R,16S)-6-hydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-9,12-diene-2,5,18-trione
|
|
SMILES |
C[C@H]1[C@H]2[C@@H](NC(=O)[C@@]23[C@@H](/C=C(/CC[C@H](C(=O)CCC3=O)O)\C)C=C1C)CC(C)C
|
|
InChI |
InChI=1S/C24H35NO4/c1-13(2)10-18-22-16(5)15(4)12-17-11-14(3)6-7-19(26)20(27)8-9-21(28)24(17,22)23(29)25-18/h11-13,16-19,22,26H,6-10H2,1-5H3,(H,25,29)/b14-11+/t16-,17+,18+,19-,22+,24-/m1/s1
|
|
InChIKey |
ULCFKAWMNZMXPT-RRRFKTONSA-N
|
|
Synonyms |
Aspochalasin P
|
|
CAS | NA | |
PubChem CID | 44471449 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 401.5 | ALogp: | 2.5 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.5 | Aromatic Rings: | 3 |
Heavy Atoms: | 29 | QED Weighted: | 0.538 |
Caco-2 Permeability: | -4.735 | MDCK Permeability: | 0.00003220 |
Pgp-inhibitor: | 0.996 | Pgp-substrate: | 0.402 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.171 |
30% Bioavailability (F30%): | 0.51 |
Blood-Brain-Barrier Penetration (BBB): | 0.982 | Plasma Protein Binding (PPB): | 87.57% |
Volume Distribution (VD): | 0.56 | Fu: | 8.97% |
CYP1A2-inhibitor: | 0.033 | CYP1A2-substrate: | 0.259 |
CYP2C19-inhibitor: | 0.472 | CYP2C19-substrate: | 0.807 |
CYP2C9-inhibitor: | 0.212 | CYP2C9-substrate: | 0.114 |
CYP2D6-inhibitor: | 0.014 | CYP2D6-substrate: | 0.085 |
CYP3A4-inhibitor: | 0.841 | CYP3A4-substrate: | 0.328 |
Clearance (CL): | 14.684 | Half-life (T1/2): | 0.235 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.282 |
Drug-inuced Liver Injury (DILI): | 0.097 | AMES Toxicity: | 0.21 |
Rat Oral Acute Toxicity: | 0.714 | Maximum Recommended Daily Dose: | 0.75 |
Skin Sensitization: | 0.342 | Carcinogencity: | 0.82 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.95 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004462 | 0.950 | D09PJX | 0.246 | ||||
ENC005810 | 0.787 | D0D2TN | 0.238 | ||||
ENC003740 | 0.750 | D06YFA | 0.231 | ||||
ENC001855 | 0.733 | D0W2EK | 0.229 | ||||
ENC004242 | 0.642 | D0I5DS | 0.228 | ||||
ENC005136 | 0.622 | D05AFC | 0.222 | ||||
ENC005825 | 0.594 | D0K7LU | 0.221 | ||||
ENC002049 | 0.486 | D09WYX | 0.221 | ||||
ENC003433 | 0.480 | D04SFH | 0.217 | ||||
ENC003245 | 0.449 | D0L7LC | 0.214 |